Retention time of the compound in mixed human liver microsomes treated with 20(S)-protopanaxadiol at 50 uM after 60 mins by liquid chromatography-electrospray ionization ion trap mass spectrometry
Drug level in human hepatocytes treated with 20(S)-protopanaxadiol at 50 uM after 180 mins by liquid chromatography-electrospray ionization ion trap mass spectrometry
Drug metabolism in mixed human liver microsomes assessed as metabolite 7-2 ((2S,3S,4S,5R,6S)-6-(2-((2R,5S)-5-((3S,5R,8R,9R,10R,12R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-5-methyltetrahydrofuran-2-yl)propan-2-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid) formation at 50 uM after 120 mins by liquid chromatography-electrospray ionization ion trap mass spectrometry in presence of UDPGA
Drug excretion in Sprague-Dawley rat feces treated with 20(S)-protopanaxadiol at 100 mg/kg/day, po qd for 11 days administered via gavage by liquid chromatography-electrospray ionization ion trap mass spectrometry
Retention time of the compound treated with 20(S)-protopanaxadiol at 100 uM measured after 60 mins by liquid chromatography-electrospray ionization ion trap mass spectrometry in presence of 10 uM 3-chloroperoxybenzoic acid
Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring cell survival at 10 uM after 72 hrs by MTT assay (Rvb = 104 +/- 8%)
Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring cell survival at 5 uM after 72 hrs by MTT assay (Rvb = 104 +/- 8%)
Reversal of Pgp-mediated paclitaxel resistance in human KBV cells assessed as cell viability at 10 uM in presence of paclitaxel incubated for 72 hrs by MTT assay
Reversal of Pgp-mediated paclitaxel resistance in human KBV cells assessed as cell viability at 5 uM in presence of paclitaxel incubated for 72 hrs by MTT assay